Login to Your Account

Kynamro dealt to newco Kastle Therapeutics for potential $95M

By Marie Powers
News Editor

Tuesday, May 3, 2016

Eight years after Ionis Pharmaceuticals Inc. selected then-independent Genzyme Corp. as the partner for its phase III lipid-lowering drug, mipomersen, in a potential $1.9 billion deal, the Carlsbad, Calif.-based company dealt the commercial asset, Kynamro, to start-up Kastle Therapeutics LLC for peanuts.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription